Called Donanemab, this treatment from Eli Lilly will be sold under its brand name, Kisunla, and works as an intravenous ...
On paper, Alzheimer’s disease should be an uncomplicated market for drugmakers. There are millions of potential patients, who ...
The US Food and Drug Administration approved Donanemab, also called Kisunla. Tuesday's decision put the monoclonal antibody ...
Alzheimer’s patients can temporarily lessen their symptoms with a recent FDA-approved drug that removes amyloid, or protein, ...
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
Medicare (and Medicare Advantage) provide some coverage for dementia, beginning with the diagnosis, says Baumgart.
British patients with early-stage Alzheimer’s disease are flying to New York to be treated with new wonder drugs following ...
The new drug, Kisunla, has the potential to be a blockbuster for the company and generate billions in revenue. But despite ...
Lantheus is expanding its holdings of PET imaging agents for Alzheimer’s disease, with the acquisition of Meilleur ...
With the first wave of Alzheimer’s disease drugs reaching the market, investors continue to seek out the next big advance in ...
The company's diabetes and obesity care treatments, Mounjaro and Zepbound, continue to support unprecedented growth for Lilly in a heated race with its rival Novo Nordisk, the maker of glucagon-like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback